<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Staphylococcus aureus bacteremia in children: Epidemiology and clinical features</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Staphylococcus aureus bacteremia in children: Epidemiology and clinical features</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Staphylococcus aureus bacteremia in children: Epidemiology and clinical features</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Vance G Fowler, Jr, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Daniel J Sexton, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sheldon L Kaplan, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Morven S Edwards, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Carrie Armsby, MD, MPH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 12, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span><em>Staphylococcus aureus</em> is a leading cause of both community- and healthcare-associated bacteremia. <em>S. aureus</em> bacteremia (SAB) is associated with increased morbidity and mortality, even with appropriate therapy.</p><p>The epidemiology and clinical features of SAB in children will be reviewed here. The management and outcome of SAB in children are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/5967.html" rel="external">"Staphylococcus aureus bacteremia in children: Management and outcome"</a>.)</p><p>This topic focuses specifically on bacteremia. Other issues related to <em>S. aureus</em> infections are discussed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/6057.html" rel="external">"<i>Staphylococcus aureus </i>in children: Overview of treatment of invasive infections"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/6065.html" rel="external">"Methicillin-resistant <i>Staphylococcus aureus </i>infections in children: Epidemiology and clinical spectrum"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/6025.html" rel="external">"Methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) in children: Prevention and control"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/3153.html" rel="external">"Methicillin-resistant Staphylococcus aureus (MRSA): Microbiology"</a>.)</p><p></p><p class="headingAnchor" id="H299731993"><span class="h1">EPIDEMIOLOGY</span></p><p class="headingAnchor" id="H3"><span class="h2">Incidence</span><span class="headingEndMark"> — </span>The overall incidence of pediatric SAB varies somewhat by region, ranging from 4 to 20 per 100,000 [<a href="#rid1">1-5</a>]. The incidence of SAB in children increased throughout the early 2000s to 2010s [<a href="#rid3">3,6-9</a>]. In one study, the increase was attributed largely to methicillin-resistant <em>S. aureus</em> (MRSA) bacteremia [<a href="#rid7">7</a>]. The rate of SAB among hospitalized children ranges from 1.5 to 3.5 per 1000 hospital admissions [<a href="#rid7">7,9,10</a>].</p><p>Using a large database representing 20 percent of pediatric hospitalizations in the United States, the incidence of non-neonatal methicillin-susceptible <em>S. aureus</em> (MSSA) bloodstream infections (BSIs) increased from 0.83 per 1000 admissions in 2009 to 1.98 per 1000 admissions in 2016 [<a href="#rid11">11</a>]. The study did not detect significant changes in the incidence of MRSA BSIs during the same time period. In this study, MSSA and MRSA accounted for a sizable proportion of all BSIs occurring outside of the neonatal age range (14 and 9 percent, respectively).</p><p>Rates of invasive <em>S. aureus</em> infections do not appear to have been significantly impacted by the coronavirus disease 2019 (COVID-19) pandemic and related social distancing, masking, and other infection mitigation practices. In a report from one children's hospital in the United States, rates of invasive <em>S. aureus</em> infections before and after 2020 remained stable despite considerable decreases in other bacterial infections, particularly invasive streptococcal infections (eg, pneumococcus and group A streptococcus) [<a href="#rid12">12</a>]. However, streptococcal infections subsequently rose sharply as pandemic restrictions were lifted, as discussed separately. (See  <a class="medical medical_review" href="/z/d/html/6068.html" rel="external">"Invasive group A streptococcal infections in children", section on 'Incidence'</a>.)</p><p class="headingAnchor" id="H2603597728"><span class="h2">Infection source</span><span class="headingEndMark"> — </span>Most cases of SAB in children are associated with a localized infection source (eg, bone and joint infections, skin and soft tissue infections, pneumonia) or invasive device (eg, central venous catheter). SAB without a focus of infection accounts for &lt;10 percent of SAB episodes, most of which occur in children with comorbidities [<a href="#rid13">13,14</a>].</p><p>The source of SAB differs depending on whether the infection is community- or healthcare-associated, as discussed in the following sections. </p><p class="headingAnchor" id="H3287059163"><span class="h2">Community-associated SAB</span><span class="headingEndMark"> — </span>Community-associated infections are those that occur in patients without risk factors for healthcare-associated infection (eg, no invasive devices or recent hospitalizations) with onset in the community (ie, in a nonhospitalized patient or within first 48 hours of a hospital admission). </p><p>Approximately 40 to 50 percent of SAB episodes are community-associated [<a href="#rid1">1,2,8,15-17</a>]. </p><p>In otherwise healthy children, community-associated SAB is frequently related to a focus of infection, including [<a href="#rid2">2,18,19</a>]: </p><p class="bulletIndent1"><span class="glyph">●</span>Bone and joint infections. (See  <a class="medical medical_review" href="/z/d/html/6063.html" rel="external">"Hematogenous osteomyelitis in children: Epidemiology, pathogenesis, and microbiology", section on 'Microbiology'</a> and  <a class="medical medical_review" href="/z/d/html/6032.html" rel="external">"Bacterial arthritis: Epidemiology, pathogenesis, and microbiology in infants and children", section on 'Microbiology'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Skin and soft tissue infections. (See  <a class="medical medical_review" href="/z/d/html/110529.html" rel="external">"Cellulitis and skin abscess: Epidemiology, microbiology, clinical manifestations, and diagnosis", section on 'Microbiology'</a> and  <a class="medical medical_review" href="/z/d/html/6027.html" rel="external">"Skin and soft tissue infections in children &gt;28 days: Evaluation and management"</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pneumonia – In particular, SAB may occur in children with influenza who develop a secondary <em>S. aureus</em> pneumonia [<a href="#rid20">20</a>]. (See  <a class="medical medical_review" href="/z/d/html/5979.html" rel="external">"Pneumonia in children: Epidemiology, pathogenesis, and etiology", section on 'Etiologic agents'</a> and  <a class="medical medical_review" href="/z/d/html/5973.html" rel="external">"Seasonal influenza in children: Clinical features and diagnosis", section on 'Complications'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Infective endocarditis (IE) – IE is an uncommon source of SAB in childhood. Nevertheless, <em>S. aureus</em> remains the predominant causative organism of pediatric IE causing infective endocarditis in children. (See  <a class="medical medical_review" href="/z/d/html/5768.html" rel="external">"Infective endocarditis in children", section on 'Microbiology'</a>.)</p><p></p><p>Community-associated MRSA (CA-MRSA) infection is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/6065.html" rel="external">"Methicillin-resistant <i>Staphylococcus aureus </i>infections in children: Epidemiology and clinical spectrum", section on 'CA-MRSA infection'</a>.)</p><p class="headingAnchor" id="H554817325"><span class="h2">Healthcare-associated SAB</span><span class="headingEndMark"> — </span>This category refers to infections that are acquired in a healthcare setting or that are associated with any of the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Invasive devices</p><p class="bulletIndent1"><span class="glyph">●</span>History of surgery, hospitalization, or dialysis within the past year</p><p class="bulletIndent1"><span class="glyph">●</span>Prior history of healthcare-associated <em>S. aureus</em> infection or colonization</p><p></p><p>Approximately 50 to 60 percent of SAB episodes in children are healthcare-associated [<a href="#rid1">1,2,8,15-17</a>]. </p><p>Healthcare-associated infections are further classified based upon whether onset is in the community or hospital.</p><p class="headingAnchor" id="H3757845602"><span class="h3">Community onset</span><span class="headingEndMark"> — </span>This category refers to infection in a patient with one or more of the above risk factors for healthcare-associated infection with onset in the community (ie, in a nonhospitalized patient or within first 48 hours of a hospital admission). Approximately one-third to one-half healthcare-associated SAB episodes are community onset [<a href="#rid1">1,2</a>]. </p><p>Community-onset healthcare-associated SAB typically affects children with chronic illnesses (eg, cancer, neurologic disorders, gastrointestinal disorders requiring home parenteral nutrition) [<a href="#rid16">16</a>]. The rate of community-onset healthcare-associated SAB has risen with increasing use of outpatient intravenous therapies [<a href="#rid16">16,21-24</a>]. (See <a class="local">'Intravascular catheters'</a> below.)</p><p>In one large multicenter study from Australia and New Zealand, the source of bacteremia among children with community-onset healthcare-associated SAB was as follows [<a href="#rid2">2</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Central venous catheter (CVC) or other device infection (26 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>Skin or soft tissue infection (21 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>Bone and joint infection (14 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>No identified source (19 percent) </p><p></p><p class="headingAnchor" id="H4"><span class="h3">Hospital onset</span><span class="headingEndMark"> — </span>Hospital-onset (or nosocomial) healthcare-associated infections are those that occur &gt;48 hours after hospital admission. One-half to two-thirds of healthcare-associated SAB episodes are hospital onset [<a href="#rid1">1,2,25</a>].</p><p>SAB is a leading cause of nosocomial BSIs in children, particularly among children with CVCs [<a href="#rid6">6,26-29</a>]. Preterm neonates are at particularly high risk of nosocomial SAB, which most commonly occurs in association with an indwelling CVC [<a href="#rid16">16,25,30,31</a>].</p><p>Other risk factors for nosocomial SAB in children are similar to those described in adults and relate mainly to intravascular devices, respiratory illness, and surgical wounds [<a href="#rid16">16,24,32,33</a>]. (See  <a class="medical medical_review" href="/z/d/html/2139.html" rel="external">"Epidemiology of Staphylococcus aureus bacteremia in adults", section on 'Risk factors'</a>.)</p><p>Nosocomial SAB is a serious infection with mortality ranging from 4 to 9 percent in children [<a href="#rid2">2,10,30</a>]. Nosocomial SAB also may be associated with metastatic complications, including septic pulmonary emboli and, rarely, infective endocarditis. (See  <a class="medical medical_review" href="/z/d/html/5967.html" rel="external">"Staphylococcus aureus bacteremia in children: Management and outcome", section on 'Outcome'</a> and  <a class="medical medical_review" href="/z/d/html/5768.html" rel="external">"Infective endocarditis in children"</a>.)</p><p class="headingAnchor" id="H7"><span class="h1">ANTIMICROBIAL RESISTANCE</span></p><p class="headingAnchor" id="H8"><span class="h2">Methicillin resistance</span><span class="headingEndMark"> — </span>Methicillin-resistant <em>S. aureus</em> (MRSA) was initially a healthcare-associated pathogen, with only small numbers of community-acquired cases, but it has become a prevalent community-acquired pathogen.</p><p>The epidemiology, microbiologic characteristics, and risk factors for methicillin resistance are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/6065.html" rel="external">"Methicillin-resistant <i>Staphylococcus aureus </i>infections in children: Epidemiology and clinical spectrum"</a>.)</p><p class="headingAnchor" id="H1187408235"><span class="h2">Clindamycin resistance</span><span class="headingEndMark"> — </span>Resistance to <a class="drug drug_pediatric" data-topicid="13167" href="/z/d/drug information/13167.html" rel="external">clindamycin</a> may be constitutive or inducible via the macrolide-lincosamide-streptogramin B (MLS[B]) resistance mechanism. Isolates with constitutive clindamycin resistance are fully resistant to both <a class="drug drug_pediatric" data-topicid="13276" href="/z/d/drug information/13276.html" rel="external">erythromycin</a> and clindamycin and can be detected with routine susceptibility testing. MRSA isolates with inducible resistance via the MLS(B) mechanism can develop resistance during therapy; these isolates appear susceptible to clindamycin and resistant to erythromycin by most standard techniques but can be detected using the "D test" (<a class="graphic graphic_picture graphicRef114732" href="/z/d/graphic/114732.html" rel="external">picture 1</a>). Automated systems are available that can screen for inducible resistance to clindamycin, with results comparable with the standard D test [<a href="#rid34">34</a>]. (See  <a class="medical medical_review" href="/z/d/html/467.html" rel="external">"Overview of antibacterial susceptibility testing", section on 'Inducible clindamycin resistance testing'</a>.)</p><p><a class="drug drug_pediatric" data-topicid="13167" href="/z/d/drug information/13167.html" rel="external">Clindamycin</a> resistance in community-associated <em>S. aureus</em> can have considerable regional and temporal variation. The proportion of MRSA isolates that are resistant to clindamycin has increased since the early 2000s [<a href="#rid35">35</a>]. Clinicians must remain vigilant for increasing clindamycin resistance among community-associated MRSA, especially since clindamycin is commonly used to treat these infections in children [<a href="#rid36">36,37</a>]. We suggest not using clindamycin to complete therapy for selective invasive infections associated with SAB until or unless the isolate is known to be susceptible to this agent and blood cultures are negative [<a href="#rid38">38,39</a>]. (See  <a class="medical medical_review" href="/z/d/html/5967.html" rel="external">"Staphylococcus aureus bacteremia in children: Management and outcome", section on 'Definitive therapy'</a>.)</p><p class="headingAnchor" id="H10"><span class="h2">Vancomycin resistance</span><span class="headingEndMark"> — </span><em>S. aureus</em> isolates with intermediate susceptibility or resistance to <a class="drug drug_pediatric" data-topicid="12874" href="/z/d/drug information/12874.html" rel="external">vancomycin</a> are much less common than MRSA. Bacteremia has been described [<a href="#rid40">40</a>]. These infections are discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/3165.html" rel="external">"Staphylococcus aureus bacteremia with reduced susceptibility to vancomycin"</a>.)</p><p class="headingAnchor" id="H1317836825"><span class="h2">Reduced susceptibility to ceftaroline</span><span class="headingEndMark"> — </span>Although <a class="drug drug_pediatric" data-topicid="109476" href="/z/d/drug information/109476.html" rel="external">ceftaroline</a> is not widely used in the treatment of MRSA bacteremia in children, in one report, reduced susceptibility to ceftaroline (minimum inhibitory concentration ≥2 mcg/mL) was found in almost 3 percent of 201 invasive MRSA isolates from children between the years 2015 to 2018. All isolates with reduced susceptibility were from children with healthcare-associated infections; none had received ceftaroline prior to the recovery of the MRSA isolate [<a href="#rid41">41,42</a>].</p><p class="headingAnchor" id="H11"><span class="h1">RISK FACTORS</span><span class="headingEndMark"> — </span>The following clinical conditions predispose patients to develop SAB:</p><p class="bulletIndent1"><span class="glyph">●</span>Intravascular catheters</p><p class="bulletIndent1"><span class="glyph">●</span>Indwelling foreign body or prosthesis</p><p class="bulletIndent1"><span class="glyph">●</span>Underlying medical conditions (eg, malignancy, end-stage kidney disease [ie, dialysis dependent], eczema and other dermatologic conditions)</p><p class="bulletIndent1"><span class="glyph">●</span>Nasal <em>S. aureus</em> colonization</p><p class="bulletIndent1"><span class="glyph">●</span>Injection drug use</p><p></p><p class="headingAnchor" id="H12"><span class="h2">Intravascular catheters</span><span class="headingEndMark"> — </span>Intravascular catheters serve as a direct conduit into the intravascular space, allowing easy access for pathogens such as <em>S. aureus</em> into the bloodstream.</p><p>Intravascular catheters are the most common predisposing cause for SAB in hospitalized patients and an increasingly important contributor to community-onset healthcare-associated infections [<a href="#rid16">16,21-23,26,29,32,43</a>].</p><p>In a report from the National Nosocomial Infections Surveillance System, &gt;90 percent of episodes of nosocomial bacteremia detected in patients in the pediatric intensive care unit setting were associated with central venous catheters [<a href="#rid26">26</a>]. In 144 pediatric intensive care units reporting data to the Centers for Disease Control and Prevention from 1997 through 2007, methicillin-resistant <em>S. aureus</em> (MRSA) and methicillin-susceptible <em>S. aureus</em> (MSSA) accounted for 2.6 and 5.3 percent of all catheter-associated bloodstream infections (BSIs), respectively [<a href="#rid44">44</a>].Catheter-associated infections account for approximately one-third of pediatric SAB episodes overall and up to three-quarters of nosocomial episodes [<a href="#rid14">14,16,29</a>].</p><p>The risk of bacteremia varies depending on the type of catheter (eg, peripherally inserted versus centrally inserted, tunneled versus nontunneled), insertion site (upper versus lower extremity, internal jugular versus femoral vein), and duration of catheterization. These issues are discussed in greater detail separately. (See  <a class="medical medical_review" href="/z/d/html/3806.html" rel="external">"Intravascular catheter-related infection: Epidemiology, pathogenesis, and microbiology"</a>.)</p><p class="headingAnchor" id="H13"><span class="h2">Implanted foreign body</span><span class="headingEndMark"> — </span>Any implanted foreign body that becomes infected is a potential source for SAB. Implanted devices include vascular, urologic, neurologic, and orthopedic prostheses and devices. In a report of 47 episodes of implant-associated <em>S. aureus</em> infection in pediatric patients, three cases (7 percent) had associated bacteremia; all three were associated with spinal instrumentation [<a href="#rid45">45</a>].</p><p class="headingAnchor" id="H14"><span class="h2">Underlying medical conditions</span><span class="headingEndMark"> — </span>Underlying medical conditions are associated with an increased risk of SAB in children. In a retrospective review of 164 episodes of SAB in 151 children, 74 percent of patients had an underlying medical condition, including heart disease (24 percent), malignancy (18 percent), premature birth (12 percent), gastrointestinal disorder (7 percent), transplant recipient (7 percent), and end-stage kidney disease (5 percent) [<a href="#rid16">16</a>]. Approximately one-half of cases had onset in hospital. In one study of 232 children with MRSA bacteremia, 52 percent had a comorbid condition [<a href="#rid19">19</a>].</p><p>Hemodialysis-dependent and diabetic patients have high rates of nasal and skin colonization with <em>S. aureus</em> [<a href="#rid46">46-48</a>]. Such patients are more prone to <em>S. aureus</em> infection [<a href="#rid46">46,48</a>], including SAB [<a href="#rid46">46,49</a>]. (See  <a class="medical medical_review" href="/z/d/html/1966.html" rel="external">"Tunneled hemodialysis catheter-related bloodstream infection (CRBSI): Management and prevention"</a>.)</p><p>Rare inherited defects in white blood cell function or immune responses can also predispose patients to recurrent staphylococcal infections [<a href="#rid50">50</a>]. These include:</p><p class="bulletIndent1"><span class="glyph">●</span>Hyperimmunoglobulin E recurrent infection syndrome (HIES; previously called Job syndrome) (see  <a class="medical medical_review" href="/z/d/html/3960.html" rel="external">"Autosomal dominant hyperimmunoglobulin E syndrome"</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Chronic granulomatous disease (see  <a class="medical medical_review" href="/z/d/html/3925.html" rel="external">"Chronic granulomatous disease: Pathogenesis, clinical manifestations, and diagnosis"</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Leukocyte adhesion deficiency(see  <a class="medical medical_review" href="/z/d/html/3918.html" rel="external">"Leukocyte-adhesion deficiency"</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Chediak-Higashi syndrome (see  <a class="medical medical_review" href="/z/d/html/3926.html" rel="external">"Chediak-Higashi syndrome"</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Wiskott-Aldrich syndrome (see  <a class="medical medical_review" href="/z/d/html/3953.html" rel="external">"Wiskott-Aldrich syndrome"</a>)</p><p></p><p class="headingAnchor" id="H15"><span class="h2">Nasal colonization</span><span class="headingEndMark"> — </span>The role of nasal colonization in the development of SAB was prospectively evaluated in a study in which more than 14,000 nonbacteremic, nonsurgical adults were screened for nasal <em>S. aureus</em> carriage on hospital admission [<a href="#rid51">51</a>]. Nosocomial SAB occurred significantly more often in the 24 percent of patients who were nasal carriers (1.2 versus 0.4 percent in noncarriers). Genotyping demonstrated that 80 percent of strains causing SAB in nasal carriers were endogenous. On the other hand, nasal carriers had significantly lower rates of SAB-related mortality (3 of 40 versus 13 of 41 [8 versus 32 percent]), a difference that could not be explained by differences in age or comorbidities.</p><p>Differences in the immune response of <em>S. aureus</em> carriers and noncarriers may help to explain the lower mortality among carriers. Support for this hypothesis comes from an observational study in which nasal swabs and serum samples were obtained from healthy blood donors [<a href="#rid52">52</a>]. Carriers of <em>S. aureus</em> demonstrated effective antibody response against the colonizing strain, whereas the antibody response against other strains was similar to that of noncarriers. This strain-specific immunity may contribute to the improved mortality outcome for nasal carriers compared with noncarriers. How these findings relate to children is unknown.</p><p>A more marked increase in the risk of infection has been described in patients who are colonized with MRSA at hospital admission. What role nasal carriage of <em>S. aureus</em> plays in the pathogenesis of SAB with onset in the community as opposed to the hospital is not clear. (See  <a class="medical medical_review" href="/z/d/html/6065.html" rel="external">"Methicillin-resistant <i>Staphylococcus aureus </i>infections in children: Epidemiology and clinical spectrum", section on 'Colonized individuals'</a>.)</p><p class="headingAnchor" id="H16"><span class="h2">Injection drug use</span><span class="headingEndMark"> — </span>The role of injection drug use in SAB is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/2139.html" rel="external">"Epidemiology of Staphylococcus aureus bacteremia in adults", section on 'Injection drug use'</a>.)</p><p class="headingAnchor" id="H1312096415"><span class="h1">CLINICAL FEATURES</span><span class="headingEndMark"> — </span>SAB frequently occurs in association with fever and other symptoms related to the source of infection.</p><p class="headingAnchor" id="H1773045832"><span class="h2">Sepsis</span><span class="headingEndMark"> — </span>Septic shock is characterized by signs of inadequate tissue perfusion with evidence of systemic inflammation (ie, abnormal temperature, white blood cell count, heart rate, and/or respiratory rate). (See  <a class="medical medical_review" href="/z/d/html/85767.html" rel="external">"Septic shock in children in resource-abundant settings: Rapid recognition and initial resuscitation (first hour)"</a> and  <a class="medical medical_review" href="/z/d/html/6395.html" rel="external">"Sepsis in children: Definitions, epidemiology, clinical manifestations, and diagnosis"</a>.)</p><p class="headingAnchor" id="H1312096789"><span class="h2">Toxic shock syndrome</span><span class="headingEndMark"> — </span>Toxic shock syndrome (TSS) can be due to streptococcal or staphylococcal infections. Bacteremia is common in the former but rare in staphylococcal TSS. Manifestations of TSS include fever, hypotension, and erythroderma (<a class="graphic graphic_picture graphicRef77600" href="/z/d/graphic/77600.html" rel="external">picture 2</a>). (See  <a class="medical medical_review" href="/z/d/html/3161.html" rel="external">"Staphylococcal toxic shock syndrome"</a>.)</p><p class="headingAnchor" id="H1312096954"><span class="h2">Osteomyelitis</span><span class="headingEndMark"> — </span>Children with hematogenous osteomyelitis usually present acutely with fever, constitutional symptoms (eg, irritability, decreased appetite or activity), focal findings of bone inflammation (warmth, swelling, point tenderness), and limitation of function (eg, limp, limited use of extremity). (See  <a class="medical medical_review" href="/z/d/html/6064.html" rel="external">"Hematogenous osteomyelitis in children: Clinical features and complications"</a>.)</p><p class="headingAnchor" id="H1312097068"><span class="h2">Septic arthritis</span><span class="headingEndMark"> — </span>Bacterial arthritis classically presents with acute onset (two to five days) of fever and joint pain, swelling, and limited range of motion. However, the presentation varies depending upon the age of the child and the site of infection. Osteomyelitis contiguous to the septic arthritis is common. (See  <a class="medical medical_review" href="/z/d/html/6030.html" rel="external">"Bacterial arthritis: Clinical features and diagnosis in infants and children", section on 'Clinical features'</a>.)</p><p class="headingAnchor" id="H1312097171"><span class="h2">Pneumonia</span><span class="headingEndMark"> — </span>SAB may be associated with pneumonia, with typical symptoms of fever, cough, and tachypnea. Complications such as necrotizing pneumonia, parapneumonic effusion, empyema, and lung abscess are frequently associated with <em>S. aureus</em> pneumonia. (See  <a class="medical medical_review" href="/z/d/html/5986.html" rel="external">"Community-acquired pneumonia in children: Clinical features and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/6344.html" rel="external">"Epidemiology, clinical presentation, and evaluation of parapneumonic effusion and empyema in children"</a>.)</p><p class="headingAnchor" id="H3328997885"><span class="h2">Skin and soft tissue infections</span><span class="headingEndMark"> — </span>Skin and soft tissue infections in children, particularly infections that are purulent/fluctuant, are commonly caused by <em>S. aureus</em>. Bacteremia is uncommon in uncomplicated skin and soft tissue infections but may occur in certain settings (eg, surgical wound infections, burns, patients with underlying risk factors). (See  <a class="medical medical_review" href="/z/d/html/6027.html" rel="external">"Skin and soft tissue infections in children &gt;28 days: Evaluation and management"</a>.)</p><p class="headingAnchor" id="H1312097273"><span class="h2">Intravascular catheter infection</span><span class="headingEndMark"> — </span>Patients with indwelling intravascular catheters are at risk for developing SAB. Clinical manifestations may include fever, inflammation or purulence at the insertion site, hemodynamic instability, and/or catheter dysfunction. (See  <a class="medical medical_review" href="/z/d/html/3806.html" rel="external">"Intravascular catheter-related infection: Epidemiology, pathogenesis, and microbiology"</a> and  <a class="medical medical_review" href="/z/d/html/3813.html" rel="external">"Intravascular non-hemodialysis catheter-related infection: Clinical manifestations and diagnosis"</a>.)</p><p class="headingAnchor" id="H1312096581"><span class="h2">Infective endocarditis</span><span class="headingEndMark"> — </span>Infective endocarditis, especially in community-acquired SAB, is much less frequent in children than in adults (1.4 percent in children compared with up to 30 percent in adults) [<a href="#rid15">15</a>]. The risk is higher in children with congenital heart disease and/or indwelling central venous catheters [<a href="#rid53">53</a>]. Clinical symptoms of infective endocarditis include a new or changing murmur and/or septic emboli. (See  <a class="medical medical_review" href="/z/d/html/5768.html" rel="external">"Infective endocarditis in children"</a>.)</p><p class="headingAnchor" id="H18"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology</strong> – <em>Staphylococcus aureus</em> is an important cause of both community- and healthcare-associated bacteremia. Most episodes of <em>S. aureus</em> bacteremia (SAB) in children are associated with a localized infection source (eg, bone and joint infections, pneumonia, skin and soft tissue infections) or invasive device (eg, central venous catheter). (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antibiotic resistance</strong> – Methicillin-resistant <em>S. aureus</em> (MRSA) has become a prevalent community-acquired pathogen. <em>S. aureus</em> isolates have also developed resistance to <a class="drug drug_pediatric" data-topicid="13167" href="/z/d/drug information/13167.html" rel="external">clindamycin</a> and, in rare cases, <a class="drug drug_pediatric" data-topicid="12874" href="/z/d/drug information/12874.html" rel="external">vancomycin</a>. (See <a class="local">'Antimicrobial resistance'</a> above and  <a class="medical medical_review" href="/z/d/html/6065.html" rel="external">"Methicillin-resistant <i>Staphylococcus aureus </i>infections in children: Epidemiology and clinical spectrum"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk factors</strong> – Important risk factors for SAB include (see <a class="local">'Risk factors'</a> above): </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Intravascular catheters</p><p class="bulletIndent2"><span class="glyph">•</span>Indwelling foreign body or prosthesis</p><p class="bulletIndent2"><span class="glyph">•</span>Underlying medical conditions</p><p class="bulletIndent2"><span class="glyph">•</span>Nasal <em>S. aureus</em> colonization</p><p class="bulletIndent2"><span class="glyph">•</span>Injection drug use</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features</strong> – The clinical features of SAB are largely related to the source of infection. (See <a class="local">'Clinical features'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Vanderkooi OG, Gregson DB, Kellner JD, Laupland KB. Staphylococcus aureus bloodstream infections in children: A population-based assessment. Paediatr Child Health 2011; 16:276.</a></li><li><a class="nounderline abstract_t">McMullan BJ, Bowen A, Blyth CC, et al. Epidemiology and Mortality of Staphylococcus aureus Bacteremia in Australian and New Zealand Children. JAMA Pediatr 2016; 170:979.</a></li><li><a class="nounderline abstract_t">Mejer N, Westh H, Schønheyder HC, et al. Stable incidence and continued improvement in short term mortality of Staphylococcus aureus bacteraemia between 1995 and 2008. BMC Infect Dis 2012; 12:260.</a></li><li><a class="nounderline abstract_t">Oestergaard LB, Schmiegelow MDS, Bruun NE, et al. Staphylococcus aureus Bacteremia in Children Aged 5-18 Years-Risk Factors in the New Millennium. J Pediatr 2018; 203:108.</a></li><li><a class="nounderline abstract_t">Campbell AJ, Al Yazidi LS, Phuong LK, et al. Pediatric Staphylococcus aureus Bacteremia: Clinical Spectrum and Predictors of Poor Outcome. Clin Infect Dis 2022; 74:604.</a></li><li><a class="nounderline abstract_t">Watson RS, Carcillo JA, Linde-Zwirble WT, et al. The epidemiology of severe sepsis in children in the United States. Am J Respir Crit Care Med 2003; 167:695.</a></li><li><a class="nounderline abstract_t">Gerber JS, Coffin SE, Smathers SA, Zaoutis TE. Trends in the incidence of methicillin-resistant Staphylococcus aureus infection in children's hospitals in the United States. Clin Infect Dis 2009; 49:65.</a></li><li><a class="nounderline abstract_t">Iwamoto M, Mu Y, Lynfield R, et al. Trends in invasive methicillin-resistant Staphylococcus aureus infections. Pediatrics 2013; 132:e817.</a></li><li><a class="nounderline abstract_t">Cobos-Carrascosa E, Soler-Palacín P, Nieves Larrosa M, et al. Staphylococcus aureus Bacteremia in Children: Changes During Eighteen Years. Pediatr Infect Dis J 2015; 34:1329.</a></li><li><a class="nounderline abstract_t">Klieger SB, Vendetti ND, Fisher BT, Gerber JS. Staphylococcus aureus bacteremia in hospitalized children: incidence and outcomes. Infect Control Hosp Epidemiol 2015; 36:603.</a></li><li><a class="nounderline abstract_t">Spaulding AB, Watson D, Dreyfus J, et al. Epidemiology of Bloodstream Infections in Hospitalized Children in the United States, 2009-2016. Clin Infect Dis 2019; 69:995.</a></li><li><a class="nounderline abstract_t">McNeil JC, Flores AR, Kaplan SL, Hulten KG. The Indirect Impact of the SARS-CoV-2 Pandemic on Invasive Group a Streptococcus, Streptococcus Pneumoniae and Staphylococcus Aureus Infections in Houston Area Children. Pediatr Infect Dis J 2021; 40:e313.</a></li><li><a class="nounderline abstract_t">Ligon J, Kaplan SL, Hulten KG, et al. Staphylococcus aureus bacteremia without a localizing source in pediatric patients. Pediatr Infect Dis J 2014; 33:e132.</a></li><li><a class="nounderline abstract_t">Hamdy RF, Dona D, Jacobs MB, Gerber JS. Risk Factors for Complications in Children with Staphylococcus aureus Bacteremia. J Pediatr 2019; 208:214.</a></li><li><a class="nounderline abstract_t">Suryati BA, Watson M. Staphylococcus aureus bacteraemia in children: a 5-year retrospective review. J Paediatr Child Health 2002; 38:290.</a></li><li><a class="nounderline abstract_t">Burke RE, Halpern MS, Baron EJ, Gutierrez K. Pediatric and neonatal Staphylococcus aureus bacteremia: epidemiology, risk factors, and outcome. Infect Control Hosp Epidemiol 2009; 30:636.</a></li><li><a class="nounderline abstract_t">Asgeirsson H, Gudlaugsson O, Kristinsson KG, et al. Low mortality of Staphylococcus aureus bacteremia in Icelandic children: nationwide study on incidence and outcome. Pediatr Infect Dis J 2015; 34:140.</a></li><li><a class="nounderline abstract_t">Miles F, Voss L, Segedin E, Anderson BJ. Review of Staphylococcus aureus infections requiring admission to a paediatric intensive care unit. Arch Dis Child 2005; 90:1274.</a></li><li><a class="nounderline abstract_t">Hamdy RF, Hsu AJ, Stockmann C, et al. Epidemiology of Methicillin-Resistant Staphylococcus aureus Bacteremia in Children. Pediatrics 2017; 139.</a></li><li><a class="nounderline abstract_t">Dawood FS, Chaves SS, Pérez A, et al. Complications and associated bacterial coinfections among children hospitalized with seasonal or pandemic influenza, United States, 2003-2010. J Infect Dis 2014; 209:686.</a></li><li><a class="nounderline abstract_t">Steinberg JP, Clark CC, Hackman BO. Nosocomial and community-acquired Staphylococcus aureus bacteremias from 1980 to 1993: impact of intravascular devices and methicillin resistance. Clin Infect Dis 1996; 23:255.</a></li><li><a class="nounderline abstract_t">Morin CA, Hadler JL. Population-based incidence and characteristics of community-onset Staphylococcus aureus infections with bacteremia in 4 metropolitan Connecticut areas, 1998. J Infect Dis 2001; 184:1029.</a></li><li><a class="nounderline abstract_t">Ruebner R, Keren R, Coffin S, et al. Complications of central venous catheters used for the treatment of acute hematogenous osteomyelitis. Pediatrics 2006; 117:1210.</a></li><li><a class="nounderline abstract_t">Tong SY, Davis JS, Eichenberger E, et al. Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management. Clin Microbiol Rev 2015; 28:603.</a></li><li><a class="nounderline abstract_t">Denniston S, Riordan FA. Staphylococcus aureus bacteraemia in children and neonates: a 10 year retrospective review. J Infect 2006; 53:387.</a></li><li><a class="nounderline abstract_t">Richards MJ, Edwards JR, Culver DH, Gaynes RP. Nosocomial infections in pediatric intensive care units in the United States. National Nosocomial Infections Surveillance System. Pediatrics 1999; 103:e39.</a></li><li><a class="nounderline abstract_t">Gaynes RP, Edwards JR, Jarvis WR, et al. Nosocomial infections among neonates in high-risk nurseries in the United States. National Nosocomial Infections Surveillance System. Pediatrics 1996; 98:357.</a></li><li><a class="nounderline abstract_t">Wisplinghoff H, Seifert H, Tallent SM, et al. Nosocomial bloodstream infections in pediatric patients in United States hospitals: epidemiology, clinical features and susceptibilities. Pediatr Infect Dis J 2003; 22:686.</a></li><li><a class="nounderline abstract_t">Hultén KG, Kaplan SL, Lamberth LB, et al. Hospital-acquired Staphylococcus aureus infections at Texas Children's Hospital, 2001-2007. Infect Control Hosp Epidemiol 2010; 31:183.</a></li><li><a class="nounderline abstract_t">Frederiksen MS, Espersen F, Frimodt-Møller N, et al. Changing epidemiology of pediatric Staphylococcus aureus bacteremia in Denmark from 1971 through 2000. Pediatr Infect Dis J 2007; 26:398.</a></li><li><a class="nounderline abstract_t">Hakim H, Mylotte JM, Faden H. Morbidity and mortality of Staphylococcal bacteremia in children. Am J Infect Control 2007; 35:102.</a></li><li><a class="nounderline abstract_t">Gray JW. A 7-year study of bloodstream infections in an English children's hospital. Eur J Pediatr 2004; 163:530.</a></li><li><a class="nounderline abstract_t">Valente AM, Jain R, Scheurer M, et al. Frequency of infective endocarditis among infants and children with Staphylococcus aureus bacteremia. Pediatrics 2005; 115:e15.</a></li><li><a class="nounderline abstract_t">Filippin L, Roisin S, Nonhoff C, et al. Evaluation of the automated Vitek 2 system for detection of various mechanisms of macrolide and lincosamide resistance in Staphylococcus aureus. J Clin Microbiol 2014; 52:4087.</a></li><li><a class="nounderline abstract_t">Khamash DF, Voskertchian A, Tamma PD, et al. Increasing Clindamycin and Trimethoprim-Sulfamethoxazole Resistance in Pediatric Staphylococcus aureus Infections. J Pediatric Infect Dis Soc 2019; 8:351.</a></li><li><a class="nounderline abstract_t">Siberry GK, Tekle T, Carroll K, Dick J. Failure of clindamycin treatment of methicillin-resistant Staphylococcus aureus expressing inducible clindamycin resistance in vitro. Clin Infect Dis 2003; 37:1257.</a></li><li><a class="nounderline abstract_t">Frank AL, Marcinak JF, Mangat PD, et al. Clindamycin treatment of methicillin-resistant Staphylococcus aureus infections in children. Pediatr Infect Dis J 2002; 21:530.</a></li><li><a class="nounderline abstract_t">Panagea S, Perry JD, Gould FK. Should clindamycin be used as treatment of patients with infections caused by erythromycin-resistant staphylococci? J Antimicrob Chemother 1999; 44:581.</a></li><li><a class="nounderline abstract_t">Drinkovic D, Fuller ER, Shore KP, et al. Clindamycin treatment of Staphylococcus aureus expressing inducible clindamycin resistance. J Antimicrob Chemother 2001; 48:315.</a></li><li><a class="nounderline abstract_t">Centers for Disease Control and Prevention (CDC). Staphylococcus aureus with reduced susceptibility to vancomycin--Illinois, 1999. MMWR Morb Mortal Wkly Rep 2000; 48:1165.</a></li><li><a class="nounderline abstract_t">McNeil JC, Sommer LM, Vallejo JG, et al. Reduced Ceftaroline Susceptibility among Invasive MRSA Infections in Children: a Clinical and Genomic Investigation. Antimicrob Agents Chemother 2022; 66:e0074522.</a></li><li><a class="nounderline abstract_t">Sommer L, Vallejo JG, Hulten KG, et al. 1367. Reduced Ceftaroline Susceptibility Among Invasive MRSA Isolates at a Tertiary Children’s HospitalReduced Ceftaroline Susceptibility Among Invasive MRSA Isolates at a Tertiary Children’s Hospital. Open Forum Infect Dis 2020; 7:S693.</a></li><li><a class="nounderline abstract_t">Carrillo-Marquez MA, Hulten KG, Mason EO, Kaplan SL. Clinical and molecular epidemiology of Staphylococcus aureus catheter-related bacteremia in children. Pediatr Infect Dis J 2010; 29:410.</a></li><li><a class="nounderline abstract_t">Burton DC, Edwards JR, Horan TC, et al. Methicillin-resistant Staphylococcus aureus central line-associated bloodstream infections in US intensive care units, 1997-2007. JAMA 2009; 301:727.</a></li><li><a class="nounderline abstract_t">Foster CE, Lamberth LB, Kaplan SL, Hulten KG. Clinical Characteristics and Outcomes of Staphylococcus aureus Implant-associated Infections in Children. Pediatr Infect Dis J 2019; 38:808.</a></li><li><a class="nounderline abstract_t">Kirmani N, Tuazon CU, Murray HW, et al. Staphylococcus aureus carriage rate of patients receiving long-term hemodialysis. Arch Intern Med 1978; 138:1657.</a></li><li><a class="nounderline abstract_t">Tuazon CU, Perez A, Kishaba T, Sheagren JN. Staphylococcus aureus among insulin-injecting diabetic patients. An increased carrier rate. JAMA 1975; 231:1272.</a></li><li><a class="nounderline abstract_t">Yu VL, Goetz A, Wagener M, et al. Staphylococcus aureus nasal carriage and infection in patients on hemodialysis. Efficacy of antibiotic prophylaxis. N Engl J Med 1986; 315:91.</a></li><li><a class="nounderline abstract_t">Jacobsson G, Dashti S, Wahlberg T, Andersson R. The epidemiology of and risk factors for invasive Staphylococcus aureus infections in western Sweden. Scand J Infect Dis 2007; 39:6.</a></li><li class="breakAll">Waldvogel FA. Staphylococcus aureus (including toxic shock). In: Principles and Practice of Infectious Diseases, 4th ed, Mandell GL, Bennett JE, Dolin R (Eds), Churchill Livingstone, New York 1995. p.1754.</li><li><a class="nounderline abstract_t">Wertheim HF, Vos MC, Ott A, et al. Risk and outcome of nosocomial Staphylococcus aureus bacteraemia in nasal carriers versus non-carriers. Lancet 2004; 364:703.</a></li><li><a class="nounderline abstract_t">Holtfreter S, Roschack K, Eichler P, et al. Staphylococcus aureus carriers neutralize superantigens by antibodies specific for their colonizing strain: a potential explanation for their improved prognosis in severe sepsis. J Infect Dis 2006; 193:1275.</a></li><li><a class="nounderline abstract_t">McNeil JC, Ligon JA, Hulten KG, et al. Staphylococcus aureus Infections in Children With Congenital Heart Disease. J Pediatric Infect Dis Soc 2013; 2:337.</a></li></ol></div><div id="topicVersionRevision">Topic 6056 Version 24.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22547946" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Staphylococcus aureus bloodstream infections in children: A population-based assessment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27533601" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Epidemiology and Mortality of Staphylococcus aureus Bacteremia in Australian and New Zealand Children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23075215" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Stable incidence and continued improvement in short term mortality of Staphylococcus aureus bacteraemia between 1995 and 2008.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30244992" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Staphylococcus aureus Bacteremia in Children Aged 5-18 Years-Risk Factors in the New Millennium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34089594" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Pediatric Staphylococcus aureus Bacteremia: Clinical Spectrum and Predictors of Poor Outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12433670" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : The epidemiology of severe sepsis in children in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19463065" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Trends in the incidence of methicillin-resistant Staphylococcus aureus infection in children's hospitals in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24062373" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Trends in invasive methicillin-resistant Staphylococcus aureus infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26780021" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Staphylococcus aureus Bacteremia in Children: Changes During Eighteen Years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25880680" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Staphylococcus aureus bacteremia in hospitalized children: incidence and outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30534940" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Epidemiology of Bloodstream Infections in Hospitalized Children in the United States, 2009-2016.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34250979" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : The Indirect Impact of the SARS-CoV-2 Pandemic on Invasive Group a Streptococcus, Streptococcus Pneumoniae and Staphylococcus Aureus Infections in Houston Area Children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24732394" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Staphylococcus aureus bacteremia without a localizing source in pediatric patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30879729" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Risk Factors for Complications in Children with Staphylococcus aureus Bacteremia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12047699" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Staphylococcus aureus bacteraemia in children: a 5-year retrospective review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19496643" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Pediatric and neonatal Staphylococcus aureus bacteremia: epidemiology, risk factors, and outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24992124" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Low mortality of Staphylococcus aureus bacteremia in Icelandic children: nationwide study on incidence and outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16301556" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Review of Staphylococcus aureus infections requiring admission to a paediatric intensive care unit.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28562284" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Epidemiology of Methicillin-Resistant Staphylococcus aureus Bacteremia in Children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23986545" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Complications and associated bacterial coinfections among children hospitalized with seasonal or pandemic influenza, United States, 2003-2010.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8842259" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Nosocomial and community-acquired Staphylococcus aureus bacteremias from 1980 to 1993: impact of intravascular devices and methicillin resistance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11574918" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Population-based incidence and characteristics of community-onset Staphylococcus aureus infections with bacteremia in 4 metropolitan Connecticut areas, 1998.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16585317" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Complications of central venous catheters used for the treatment of acute hematogenous osteomyelitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26016486" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16476482" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Staphylococcus aureus bacteraemia in children and neonates: a 10 year retrospective review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10103331" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Nosocomial infections in pediatric intensive care units in the United States. National Nosocomial Infections Surveillance System.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8784356" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Nosocomial infections among neonates in high-risk nurseries in the United States. National Nosocomial Infections Surveillance System.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12913767" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Nosocomial bloodstream infections in pediatric patients in United States hospitals: epidemiology, clinical features and susceptibilities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20001603" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Hospital-acquired Staphylococcus aureus infections at Texas Children's Hospital, 2001-2007.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17468649" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Changing epidemiology of pediatric Staphylococcus aureus bacteremia in Denmark from 1971 through 2000.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17327189" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Morbidity and mortality of Staphylococcal bacteremia in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15241687" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : A 7-year study of bloodstream infections in an English children's hospital.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15601815" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Frequency of infective endocarditis among infants and children with Staphylococcus aureus bacteremia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25210074" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Evaluation of the automated Vitek 2 system for detection of various mechanisms of macrolide and lincosamide resistance in Staphylococcus aureus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30011009" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Increasing Clindamycin and Trimethoprim-Sulfamethoxazole Resistance in Pediatric Staphylococcus aureus Infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14557972" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Failure of clindamycin treatment of methicillin-resistant Staphylococcus aureus expressing inducible clindamycin resistance in vitro.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12182377" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Clindamycin treatment of methicillin-resistant Staphylococcus aureus infections in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10588329" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Should clindamycin be used as treatment of patients with infections caused by erythromycin-resistant staphylococci?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11481309" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Clindamycin treatment of Staphylococcus aureus expressing inducible clindamycin resistance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11266244" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Staphylococcus aureus with reduced susceptibility to vancomycin--Illinois, 1999.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36165630" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Reduced Ceftaroline Susceptibility among Invasive MRSA Infections in Children: a Clinical and Genomic Investigation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : 1367. Reduced Ceftaroline Susceptibility Among Invasive MRSA Isolates at a Tertiary Children’s HospitalReduced Ceftaroline Susceptibility Among Invasive MRSA Isolates at a Tertiary Children’s Hospital</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20431380" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Clinical and molecular epidemiology of Staphylococcus aureus catheter-related bacteremia in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19224749" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Methicillin-resistant Staphylococcus aureus central line-associated bloodstream infections in US intensive care units, 1997-2007.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31033905" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Clinical Characteristics and Outcomes of Staphylococcus aureus Implant-associated Infections in Children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/718314" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Staphylococcus aureus carriage rate of patients receiving long-term hemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1172956" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Staphylococcus aureus among insulin-injecting diabetic patients. An increased carrier rate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3523240" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Staphylococcus aureus nasal carriage and infection in patients on hemodialysis. Efficacy of antibiotic prophylaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17366006" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : The epidemiology of and risk factors for invasive Staphylococcus aureus infections in western Sweden.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17366006" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : The epidemiology of and risk factors for invasive Staphylococcus aureus infections in western Sweden.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15325835" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Risk and outcome of nosocomial Staphylococcus aureus bacteraemia in nasal carriers versus non-carriers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16586365" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Staphylococcus aureus carriers neutralize superantigens by antibodies specific for their colonizing strain: a potential explanation for their improved prognosis in severe sepsis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26619497" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Staphylococcus aureus Infections in Children With Congenital Heart Disease.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
